Altamira Therapeutics Ltd. (CYTO) Special Call December 11, 2023 8:30 AM ET
Company Participants
Thomas Meyer - Founder, Chairman and CEO
Conference Call Participants
Operator
Good morning, and welcome to Altamira Therapeutics December 23, 2023 Investor Business Update Conference Call. On today's call is Thomas Meyer, Altamira Therapeutics' Founder, Chairman and Chief Executive Officer.
Earlier today, Altamira issued a news release providing a highlight of its business updates which we will be discussing on this call. The release is available on the company's website at ir.altenurtherapeutics.com and has been filed with the SEC.
During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial, business performance, strategies or expectations.
Forward-looking statements are based on the company's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials, the clinical utility of product candidates, the timing or likelihood of regulatory filings and approvals, intellectual property positions and financial position as well as those described in the Risk Factors section of the company's annual report on Form 6-K and future filings with the Securities and Exchange Commission.
In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon representing its views as of any subsequent date. While it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so even if it means change.
With that, I will hand the call over to Altamira Therapeutics CEO, Thomas Meyer.
Thomas Meyer
Thank
- Read more current CYTOF analysis and news
- View all earnings call transcripts